Banca de DEFESA: ALINE MARIA VASCONCELOS QUEIROZ

Uma banca de DEFESA de DOUTORADO foi cadastrada pelo programa.
STUDENT : ALINE MARIA VASCONCELOS QUEIROZ
DATE: 22/07/2024
TIME: 13:00
LOCAL: Sessão de videoconferência: https://meet.google.com/opg-xrif-bdx
TITLE:

EVALUATION OF VACCINE FORMULATIONS IN THE CONTEXT OF CHAGAS DISEASE EXPERIMENTAL MODEL

KEY WORDS:

Trypanosoma cruzi; Chimeric recombinant antigens; Triatoma virus; Chimeric vaccines; Murine model.

PAGES: 94
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUMMARY:

An important neglected tropical condition, the Chagas disease, though endemic to the Americas, has become a global health concern. The challenges in therapeutics highlight the urgency of developing vaccines to control this disease. Preclinical studies have expanded into a range of vaccine platforms and formulations to be tested. The presentation of new vaccine formulations using chimeric recombinant antigens of the etiological agent offers a consequent improvement in immunogenicity. At this juncture, this study's main focus was the applicability of chimeric vaccines with different Trypanosoma cruzi antigens in association or not with immunoadjuvant molecules. Thus, the immunoadjuvant capacity of three structural polypeptides from Triatoma virus in a mix form (VP1+VP2+VP3: VPs) was presented and investigated, as well as vaccine formulations with the proteins (IBMP-8.1, IBMP- 8.2, IBMP-8.3 and IBMP-8.4) in an antigenic mixture (Mix-IBMP) associated or not with VPs and known adjuvants (Freund's Incomplete Adjuvant - FIA and Aluminum Hydroxide - Alum) through humoral immunity at different times during immunization protocols with two and three doses in animal models. For this purpose, female Balb/c mice (Mus musculus) were immunized in a two-dose protocol and separated into five groups: Mix-IBMP, Mix+FIA, Mix+Alum, Mix+VPs and negative control. In the three-immunization protocol, the groups were: FIA, Alum, Mix-IBMP, Mix+FIA, Mix+Alum and negative control. presented together with an experimental infection protocol with T. cruzi. Animals from all protocols had specific murine antibody profiles of the IgG type and its subtypes (IgG1, IgG2a, IgG2b and IgG3) determined by immunoenzymatic testing from serum samples. The data demonstrate the ability of VPs to induce good levels of IgG, IgG2b and IgG3 antibodies and no induction of IgG1, thus characterizing the humoral immunostimulatory property of these polypeptides; suggest that proteins in the Mix form direct a low presence or total absence of IgG1, an interesting possibility for intracellular responses; show that aluminum hydroxide presents similar performance in different concentrations and finally, the optimization of two immunization protocols in a murine model in the context of Chagas disease, as well as the importance of the booster dose. However, immunized animals recognize the parasite and infected animals recognize IBMPs. This work presents a pioneering perspective in the panorama of T. cruzi chimeras associated with VPs and FIA and a good association with the most used adjuvant in vaccines. The findings provide valuable insights to foster the development of chimeric vaccines for human infections caused by trypanosomatids, such as Chagas disease.

COMMITTEE MEMBERS:
Externo à Instituição - MICÁSSIO FERNANDES DE ANDRADE - UFERSA
Externa à Instituição - ALINE RIMOLDI RIBEIRO
Externo à Instituição - DIEGO MARCELO GUERIN AGUILAR - UPV/EHU
Interna - 1055045 - MARCELA ABBOTT GALVAO URURAHY
Presidente - 2275890 - MARCELO DE SOUSA DA SILVA
Externo ao Programa - 2213126 - VALTER FERREIRA DE ANDRADE NETO - null